CARDIOPROTECTIVE AND METABOLIC EFFECTS OF ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH SUCH COMORBIDITIES AS ARTERIAL HYPERTENSION, TYPE 2 DIABETES MELLITUS, AND OBESITY

  2. 2023
  3. CARDIOPROTECTIVE AND METABOLIC EFFECTS OF ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH SUCH COMORBIDITIES AS ARTERIAL HYPERTENSION, TYPE 2 DIABETES MELLITUS, AND OBESITY

Dunaieva I. P., Kravchun N. O., Ilchenko І. A.

CARDIOPROTECTIVE AND METABOLIC EFFECTS OF ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH SUCH COMORBIDITIES AS ARTERIAL HYPERTENSION, TYPE 2 DIABETES MELLITUS, AND OBESITY

Show/Download

About the author:

Dunaieva I. P., Kravchun N. O., Ilchenko І. A.

Heading:

CLINICAL AND EXPERIMENTAL MEDICINE

Type of article:

Scientific article

Annotation:

Today, high rates of growth of such chronic diseases as hypertension, type 2 diabetes mellitus and obesity are noted in the world. The combination of these pathologies increases the risk of developing fatal cardiovascular complications and cardiac mortality tenfold. A reduction in systolic blood pressure of every 10 mmHg, as shown in the UKPDS study (1998), was associated with a 15% reduction in mortality. The most expedient and justified for now is the appointment for complex treatment of patients with comorbid pathology, antihypertensive drugs that inhibit excessive activation of the ranin-angiotensin-aldosterone system (RAAS), in particular, ACE inhibitors and ARB II. This article highlights the main cardioprotective and metabolic properties of these groups of drugs and the specifics of their appointment, taking into account concomitant pathology.

Tags:

arterial hypertension, obesity, ramipril, telmisartan, type 2 diabetes mellitus

Bibliography:

  1. Nowakowska M, Zghebi SS, Ashcroft DM, Buchan I, Chew-Graham C, Holt T, et al. The comorbidity burden of type 2 diabetes mellitus: patterns, clusters and predictions from a large English primary care cohort. BMC Med. 2019 Jul 25;17(1):145. DOI: 10.1186/s12916-019- 1373-y. Erratum in: BMC Med. 2020 Jan 25;18(1):22.
  2. Bassand JP, Accetta G, Al Mahmeed W, Corbalan R, Eikelboom J, Fitzmaurice DA, et al. Risk factors for death, stroke, and bleeding in 28,628 patients from the GARFIELD-AF registry: Rationale for comprehensive management of atrial fibrillation. PLoS One. 2018 Jan 25;13(1):e0191592. DOI: 10.1371/journal.pone.0191592.
  3. Serhiyenko V, Serhiyenko O. Diabetes mellitus and arterial hypertension. Mìžnarodnij endokrinologìčnij žurnal [Internet]. 2021 Apr 30 [cited 2023 May 21];17(2):175-88. Available from: https://iej.zaslavsky.com.ua/index. php/ journal/article/view/22.
  4. Cowie CC. Diabetes Diagnosis and Control: Missed Opportunities to Improve Health: The 2018 Kelly West Award Lecture. Diabetes Care. 2019 Jun;42(6):994-1004. DOI: 10.2337/dci18-0047.
  5. HbA1c targets in type 2 diabetes: guidelines and evidence. Drug Ther Bull. 2013 Apr;51(4):42-5. DOI: 10.1136/dtb.2013.4.0172.
  6. Pavlou DI, Paschou SA, Anagnostis P, Spartalis M, Spartalis E, Vryonidou A, et al. Hypertension in patients with type 2 diabetes mellitus: Targets and management. Maturitas. 2018 Jun;112:71-77. DOI: 10.1016/j.maturitas 2018.03.013.
  7. Przezak A. Bielka W, Pawlik A. Hypertension and Type 2 Diabetes-The Novel Treatment Possibilities. Int J Mol Sci. 2022 Jun 10;23(12):6500. DOI: 10.3390/ijms23126500.
  8. Kim HJ, Kim Kl. Blood Pressure Target in Type 2 Diabetes Mellitus. Diabetes Metab J. 2022 Sep;46(5):667-674. DOI: 10.4093/dmi 2022.0215.
  9. Li JC, Cheng PC, Huang CN, Jian LF, Wu Y, Lin CL. Antihypertensive treatment improves glycemic control in patients with newly diagnosed type 2 diabetes mellitus: A prospective cohort study. Front Endocrinol (Lausanne). 2022 Sep 9;13:935561. DOI: 10.3389/fendo.2022935561.
  10. Gupta S, Jhawat V. Induction of Type 2 Diabetes Mellitus with Antihypertensive Therapy: Is There Any Role of Alpha Adducin, ACE, and IRS-1 Gene? Value Health Reg Issues. 2017 May;12:90-98. DOI: 10.1016/j.vhri 2016.10.005.
  11. Langendoen-Gort M, Al-Jabr H, Hugtenburg JG, Rutters F, de Wit M, Bhattacharya D, et al. A personalised intervention programme aimed at improving adherence to oral antidiabetic and/or antihypertensive medication in people with type 2 diabetes mellitus, the INTENSE study: study protocol for a randomised controlled trial. Trials. 2022 Sep 2;23(1):731. DOI: 10.1186/s13063-022-06491-7.
  12. Oktora MP, Kerr KP, Hak E, Denig P. Rates, determinants and success of implementing deprescribing in people with type 2 diabetes: A scoping review. Diabet Med. 2021 Feb;38(2):e14408. DOI: 10.1111/dme.14408.
  13. Laurent S. Antihypertensive drugs. Pharmacol Res. 2017 Oct;124:116-125. DOI: 10.1016/j.phrs.2017.07.026.
  14. Мolotiagin D. Effectiveness of different treatment regimens in patients with coronary heart disease and arterial hypertension with type 2 diabetes mellitus. Ukrainian Journal of Medicine, Biology and Sports. 2020;5(3):208-214. DOI: https://doi.org/10.26693/jmbs05.03.208.
  15. Cavender MA, Wirka RC. Blood pressure lowering in the prevention of type 2 diabetes. Lancet. 2021 Nov 13;398(10313):1778-1779. DOI: 10.1016/S0140-6736(21)02340-0.
  16. Avogaro A, Barillà F, Cavalot F, Consoli A, Federici M, Mancone M, et al. Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies. Nutr Metab Cardiovasc Dis. 2021 Jun 7;31(6):1671- 1690. DOI: 10.1016/j.numecd.2021.02.029.
  17. Antza C, Doundoulakis I, Stabouli S, Kotsis V. American, European and international hypertension guidelines: Time to shake hands? Int J Cardiol Hypertens. 2020 Dec 17;8:100075. DOI: 10.1016/j.ijchy.2020.100075.
  18. Katsiki N, Ferrannini E, Mantzoros C. New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician’s perspective. Metabolism. 2020 Jun;107:154218. DOI: 10.1016/j.metabol.2020.154218.
  19. Böhm M, Pogue J, Kindermann I, Pöss J, Koon T, Yusuf S. Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure. Eur J Heart Fail. 2014 Mar;16(3):325-33. DOI: 10.1002/ejhf.23.
  20. Abuissa H, Jones PG, Marso SP, O’Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 2005 Sep 6;46(5):821-6. DOI: 10.1016/j.jacc.2005.05.051.
  21. Pfeffer MA, Claggett B, Lewis EF, Granger CB, Køber L, Maggioni AP, et al. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med. 2021 Nov 11;385(20):1845-1855. DOI: 10.1056/NEJMoa2104508. Erratum in: N Engl J Med. 2021 Dec 30;385(27):2592.
  22. Pertseva N. Dynamics of Endothelial Function Impairment in Patients with Initial Poor Compensation of Type 2 Diabetes Mellitus in Correction of Hypertension with Angiotensin II Receptor Antagonists during a year. Mìžnarodnij endokrinologìčnij žurnal [Internet]. 2022 Feb 18 [cited 2023 May 21];7(63):13-7. Available from: https://iej.zaslavsky.com.ua/index. php/journal/article/view/837.
  23. Chmyr N. Dynamics of endocrine and metabolic changes among patients with coronary artery disease, type 2 diabetes mellitus and metabolic syndrome while treating with telmisartan. Mìžnarodnij endokrinologìčnij žurnal [Internet]. 2022 Mar 27 [cited 2023 May 21];18(1):22-35. Available from: https://iej.zaslavsky.com.ua/index.php/journal/article/view/1142.
  24. Rekovets OL, Sirenko YM, Torbas OO, Kushnir CM, Prymak GF. Vplyv blokatoriv retseptoriv anhiotenzynu II na zminy ofisnoho, tsentralʹnoho arterialʹnoho tysku ta tsyrkadnistʹ arterialʹnoho tysku zalezhno vid rankovoho abo vechirnʹoho pryyomu. UKZH [Internet]. 2019 Hrud 24 [cited 2023 Trav 21];26(5):23-2. Dostupno: https://ucardioj.com.ua/index. php/UJC/article/view/195.

Publication of the article:

«Bulletin of problems biology and medicine», 2023 Issue 2, 169, 211-215 pages, index UDC 616.12-008.331.1+616.379-008.64]-056.257-085.225.2

DOI:

10.29254/2077-4214-2023-2-160-211-215

2023 Issue 2, 169
arterial hypertension obesity ramipril telmisartan type 2 diabetes mellitus
29.06.2023
Was this article helpful?
3
2